First patients treated with new BEAMOTION technology in routine clinical practice

One patient with 3 fibroadenomas treated in 43 minutes

Malakoff, November 30, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today that at the Marienhospital in Bottrop, Germany, the company’s new BEAMOTION technology was utilized for the first time in standard clinical practice.

Two patients were treated and in both cases, the procedure was performed under simple, local anesthesia. The recently CE-marked technology allows significantly faster treatment compared to historical norms. One of the two patients presented with three fibroadenomas, all of which were treated in a total of 43 minutes.

The rollout of the new BEAMOTION technology started with the upgrade of the existing Echopulse® system installed at the Marienhospital and will continue with further upgrades and new installations in the coming weeks and months. The clinical trials that led to the CE marking of BEAMOTION had been conducted using conscious sedation. However, in this standard clinical setting, procedures were conducted using a simple local anesthetic. Four breast fibroadenomas were treated in 11, 15, 16, and 18 minutes respectively.

“The treatments went remarkably smoothly. Treatment duration is now equivalent to the fastest surgical and thermoablative methods – but without the invasive or minimally invasive character of those techniques.” says Dr. Kolberg, head of the gynecology and obstetrics department of the Marienhospital Bottrop. “With BEAMOTION accelerating the treatment by a factor of up to five, discussion about research in the oncology field is a realistic option”.

“We had been waiting for these first treatments to be done in a routine clinical setting to have the final confirmation, but we are now proud to confirm the significant treatment acceleration our technology brings to the table under local anesthesia.” adds David Caumartin, CEO Theraclion. “Echopulse is now not only the only system for non-invasive ablation of benign breast tumors and thyroid nodules, but also delivers therapeutic ultrasound faster than anyone else in the industry.”

About Theraclion
Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 30 people, 53 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402

Contacts:
Theraclion
David Caumartin
CEO
Tel.: +33 (0)1 55 48 90 70
david.caumartin@theraclion.com

NewCap
Financial Communications & Investors relations
Emmanuel Huynh / Valentine Brouchot
Tel.: +33 (0)1 44 71 94 94
theraclion@newcap.fr

Kalima
Press Relations
Estelle Reine-Adélaïde / Florence Calba
Tel.: +33 (0)1 44 90 82 54
era@kalima-rp.fr